Skip to main content
. 2017 Jun 30;10(4):669–678. doi: 10.1016/j.tranon.2017.06.003

Figure 4.

Figure 4

Treatment with CCNU + 9-ING-41 leads to regression of intracranial GBM12 PDX tumors. (A) Kaplan-Meier survival analysis of treated mice bearing intracranial human GBM12 PDX-Tom-Luc tumors. Mice were staged and randomized based on BLI. Mice were treated two times a week with vehicle control (DMSO; n = 5), 5 mg/kg CCNU (n = 5), 70 mg/kg 9-ING-41 (n = 5), and CCNU + 9-ING-41 (n = 5) as indicated. The median survival in the vehicle control, 9-ING-41, and CCNU groups was 24, 24, and 26 days, respectively. Four of five 9-ING-41 + CCNU–treated animals were intentionally euthanized (censored) for histological analysis of brain at day 74 (m1618) and day 105 (m1603, m1616, m1617) despite being healthy and luciferase-signal free. The combination of CCNU and 9-ING-41 significantly prolonged survival of animals as compared to CCNU-treated group (P < .05). (B) Animal weight was measured weekly. Graph, mean animal weight; bars, SE. (C) Representative IVIS images of GBM12-bearing animals treated as indicated.